Literature DB >> 35882380

Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization.

Ankit D Kanthe1,2, Miriam R Carnovale3, Joshua S Katz3, Susan Jordan3, Mary E Krause1, Songyan Zheng1, Andrew Ilott1, William Ying1, Wei Bu4, Mrinal K Bera4, Binhua Lin4, Charles Maldarelli2,5, Raymond S Tu2.   

Abstract

Protein adsorption on surfaces can result in loss of drug product stability and efficacy during the production, storage, and administration of protein-based therapeutics. Surface-active agents (excipients) are typically added in protein formulations to prevent undesired interactions of proteins on surfaces and protein particle formation/aggregation in solution. The objective of this work is to understand the molecular-level competitive adsorption mechanism between the monoclonal antibody (mAb) and a commercially used excipient, polysorbate 80 (PS80), and a novel excipient, N-myristoyl phenylalanine-N-polyetheramine diamide (FM1000). The relative rate of adsorption of PS80 and FM1000 was studied by pendant bubble tensiometry. We find that FM1000 saturates the interface faster than PS80. Additionally, the surface-adsorbed amounts from X-ray reflectivity (XRR) measurements show that FM1000 blocks a larger percentage of interfacial area than PS80, indicating that a lower bulk FM1000 surface concentration is sufficient to prevent protein adsorption onto the air/water interface. XRR models reveal that with an increase in mAb concentration (0.5-2.5 mg/mL: IV based formulations), an increased amount of PS80 concentration (below critical micelle concentration, CMC) is required, whereas a fixed value of FM1000 concentration (above its relatively lower CMC) is sufficient to inhibit mAb adsorption, preventing mAb from co-existing with surfactants on the surface layer. With this observation, we show that the CMC of the surfactant is not the critical factor to indicate its ability to inhibit protein adsorption, especially for chemically different surfactants, PS80 and FM1000. Additionally, interface-induced aggregation studies indicate that at minimum surfactant concentration levels in protein formulations, fewer protein particles form in the presence of FM1000. Our results provide a mechanistic link between the adsorption of mAbs at the air/water interface and the aggregation induced by agitation in the presence of surfactants.

Entities:  

Keywords:  FM1000; X-ray reflectivity; air/water interface; monoclonal antibody (mAb); novel surfactants; pendant bubble tensiometry; polysorbate 80 (PS80); protein aggregation; protein formulations; silicone oil/liquid interface; surface tension

Mesh:

Substances:

Year:  2022        PMID: 35882380      PMCID: PMC9450885          DOI: 10.1021/acs.molpharmaceut.2c00152

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   5.364


  49 in total

Review 1.  Instability, stabilization, and formulation of liquid protein pharmaceuticals.

Authors:  W Wang
Journal:  Int J Pharm       Date:  1999-08-20       Impact factor: 5.875

2.  Monolayer-multilayer transitions in a lung surfactant model: IR reflection-absorption spectroscopy and atomic force microscopy.

Authors:  Lin Wang; Peng Cai; Hans-Joachim Galla; Huixin He; Carol R Flach; Richard Mendelsohn
Journal:  Eur Biophys J       Date:  2005-01-12       Impact factor: 1.733

Review 3.  Role of naturally occurring osmolytes in protein folding and stability.

Authors:  Raj Kumar
Journal:  Arch Biochem Biophys       Date:  2009-09-19       Impact factor: 4.013

4.  Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses.

Authors:  M Katakam; A K Banga
Journal:  Pharm Dev Technol       Date:  1997-05       Impact factor: 3.133

5.  A Method To Measure Protein Unfolding at an Air-Liquid Interface.

Authors:  Danielle L Leiske; Ian C Shieh; Martha Lovato Tse
Journal:  Langmuir       Date:  2016-09-19       Impact factor: 3.882

6.  Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.

Authors:  Lea L Sorret; Madison A DeWinter; Daniel K Schwartz; Theodore W Randolph
Journal:  Protein Sci       Date:  2018-03-03       Impact factor: 6.725

Review 7.  Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.

Authors:  Qi Zhang; Guihua Chen; Xinyuan Liu; Qijun Qian
Journal:  Cell Res       Date:  2007-02       Impact factor: 25.617

8.  Antibody adsorption on the surface of water studied by neutron reflection.

Authors:  Charles Smith; Zongyi Li; Robert Holman; Fang Pan; Richard A Campbell; Mario Campana; Peixun Li; John R P Webster; Steven Bishop; Rojaramani Narwal; Shahid Uddin; Christopher F van der Walle; Jian R Lu
Journal:  MAbs       Date:  2017-02-10       Impact factor: 5.857

9.  Effects of Hydrophobic Tail Length Variation on Surfactant-Mediated Protein Stabilization.

Authors:  Mckenna G Hanson; Joshua S Katz; Hua Ma; Miriam Putterman; Benjamin A Yezer; Oliver Petermann; Theresa M Reineke
Journal:  Mol Pharm       Date:  2020-10-15       Impact factor: 4.939

10.  Strategies for the assessment of protein aggregates in pharmaceutical biotech product development.

Authors:  John den Engelsman; Patrick Garidel; Ronald Smulders; Hans Koll; Bryan Smith; Stefan Bassarab; Andreas Seidl; Otmar Hainzl; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-10-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.